Blood Loss, SurgicalNCT04114253
QStat in Liver Transplant
An observational study of Blood Loss, Surgical, run by HemoSonics LLC at 1 site in United States.
Trial summary
This study will assess the clinical performance of the Quantra System with the QStat Cartridge in the liver transplant population. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Blood Loss, Surgical
- What is being tested?
- Quantra System
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- 4 Sep 2019to 12 Dec 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population includes subjects 18 years or older undergoing deceased donor liver transplant.
Who may be able to join
- Subject is ≥ 18 years of age
- Subject is undergoing deceased donor liver transplant and is a candidate for a TEG test to be performed to access coagulopathy during surgery.
- Subject is willing to participate, and is willing to consent (either prospectively or by deferred consent)
Who cannot join
- Subject is younger than 18 years of age
- Subject is known to have received antifibrinolytic therapy immediately prior to the start of liver transplantation surgery.
- Subject is unable to provide written informed consent (either prior to performing any study related procedures or by deferred consent)
- Subject is currently enrolled in a distinct study that might confound the results of the proposed study
- Subject is affected by a condition that, in the opinion of the clinical team, may pose additional risks
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Minnesota
Minneapolis, Minnesota, 55455
About this study
Official title: Evaluation of the Clinical Performance of the Quantra System With the QStat Cartridge in Liver Transplant
This study will assess the clinical performance of the Quantra System with the QStat Cartridge in the liver transplant population.
Read the detailed description
The Quantra System is a fully integrated and automated in vitro diagnostic device which uses SEER Sonorheometry, an ultrasound-based technology, to characterize the viscoelastic propoerties of a whole blood sample during coagulation. The Quantra QStat Cartridge was developed to monitor hemostasis in the trauma and liver transplant populations which may experience a range of coagulopathies of various etiologies including fibrinolytic defects.
This single-center, prospective, observational stuey will evaluate the performance of the Quantra System with the QStat Cartridge as compared to corresponding measures determined using the TEG 5000.
- Conditions
- Blood Loss, Surgical
- Being tested
- Quantra System
- Keywords
- Viscoelastic testing, Coagulation, Quantra, Hemostasis
- Medical subject headings
- Blood Loss, Surgical, Thrombosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quantra SystemDiagnostic test
Also called Quantra QStat Cartridge
Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
| Study group | Role | What they receive |
|---|---|---|
| Liver transplant patients | Adult patients undergoing deceased donor liver transplantation. Receives: Diagnostic Test: Quantra System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparison of Quantra Clot Time results to TEG R results
Coagulation function assessed by Quantra and TEG 5000
Measured: Baseline, after induction of anesthesia, before surgical incision
Comparison of Quantra Clot Stiffness results to TEG MA results
Coagulation function assessed by Quantra and TEG 5000
Measured: Baseline, after induction of anesthesia, before surgical incision
Comparison of Quantra Clot Lysis results to TEG LI30 results
Coagulation function assessed by Quantra and TEG 5000
Measured: Baseline, after induction of anesthesia, before surgical incision
Comparison of Quantra Clot Time results to TEG R results
Coagulation function assessed by Quantra and TEG 5000
Measured: During surgery
Comparison of Quantra Clot Stiffness results to TEG MA results
Coagulation function assessed by Quantra and TEG 5000
Measured: During surgery
Comparison of Quantra Clot Lysis results to TEG LI30 results
Coagulation function assessed by Quantra and TEG 5000
Measured: During surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Oct 2019
- Study start4 Sep 2019
- Primary completion12 Aug 2020
- Study completion12 Dec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Blood Loss, SurgicalStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- HemoSonics LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04114253
- Sponsor's protocol ID
- HEMCS-029
- Status last verified
- Dec 2020
- First submitted
- 1 Oct 2019
- Last updated
- 5 Jan 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Clinical Performance of the Quantra System With the QStat Cartridge in Liver Transplant
- ClinicalTrials.gov ID
- NCT04114253
- Acronym / sponsor ID
- HEMCS-029
- Conditions
- Blood Loss, Surgical
- Keywords
- Viscoelastic testing, Coagulation, Quantra, Hemostasis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- HemoSonics LLCIndustry (pharma, biotech, devices)
- Study start
- 4 Sep 2019 (actual)
- Primary completion
- 12 Aug 2020 (actual)
- Study completion
- 12 Dec 2020 (actual)
- First posted
- 3 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will assess the clinical performance of the Quantra System with the QStat Cartridge in the liver transplant population.
Detailed description
The Quantra System is a fully integrated and automated in vitro diagnostic device which uses SEER Sonorheometry, an ultrasound-based technology, to characterize the viscoelastic propoerties of a whole blood sample during coagulation. The Quantra QStat Cartridge was developed to monitor hemostasis in the trauma and liver transplant populations which may experience a range of coagulopathies of various etiologies including fibrinolytic defects.
This single-center, prospective, observational stuey will evaluate the performance of the Quantra System with the QStat Cartridge as compared to corresponding measures determined using the TEG 5000.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Liver transplant patients | – | Diagnostic Test: Quantra SystemAdult patients undergoing deceased donor liver transplantation. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population includes subjects 18 years or older undergoing deceased donor liver transplant.
Key inclusion criteria (3 listed)
- Subject is ≥ 18 years of age
- Subject is undergoing deceased donor liver transplant and is a candidate for a TEG test to be performed to access coagulopathy during surgery.
- Subject is willing to participate, and is willing to consent (either prospectively or by deferred consent)
Key exclusion criteria (5 listed)
- Subject is younger than 18 years of age
- Subject is known to have received antifibrinolytic therapy immediately prior to the start of liver transplantation surgery.
- Subject is unable to provide written informed consent (either prior to performing any study related procedures or by deferred consent)
- Subject is currently enrolled in a distinct study that might confound the results of the proposed study
- Subject is affected by a condition that, in the opinion of the clinical team, may pose additional risks
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Quantra SystemAlso: Quantra QStat CartridgeDiagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care. | Diagnostic test | Liver transplant patients |
Primary outcome
Comparison of Quantra Clot Time results to TEG R results
Time frame: Baseline, after induction of anesthesia, before surgical incision
Coagulation function assessed by Quantra and TEG 5000
Comparison of Quantra Clot Stiffness results to TEG MA results
Time frame: Baseline, after induction of anesthesia, before surgical incision
Coagulation function assessed by Quantra and TEG 5000
Comparison of Quantra Clot Lysis results to TEG LI30 results
Time frame: Baseline, after induction of anesthesia, before surgical incision
Coagulation function assessed by Quantra and TEG 5000
Comparison of Quantra Clot Time results to TEG R results
Time frame: During surgery
Coagulation function assessed by Quantra and TEG 5000
Comparison of Quantra Clot Stiffness results to TEG MA results
Time frame: During surgery
Coagulation function assessed by Quantra and TEG 5000
Comparison of Quantra Clot Lysis results to TEG LI30 results
Time frame: During surgery
Coagulation function assessed by Quantra and TEG 5000
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jan 2021.
- Individual participant dataSharing planned: No
Related trials for Blood Loss, Surgical
Active, not recruitingObservational study
Safe and Timely Antithrombotic Removal (STAR) Registry
Hemorrhage, Surgical, Hemorrhage Postoperative
RecruitingPhase 3
Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
Blood Loss, Surgical, Coagulation Disorder
Not yet recruitingPhase 3
Tranexamic Acid to Reduce Blood Loss After Varus Derotation Osteotomy
Cerebral Palsy, Hip Surgery Corrective
RecruitingPhase 4
Carbetocin Monotherapy Versus Carbetocin Plus Oxytocin Infusion in Elective Cesarean Delivery: A Non-Inferiority Trial
Postpartum Hemorrhage, Uterine Atony
Not yet recruitingPhase 2
Effect of Vitamin C Administration on Intraoperative Bleeding in Patients Undergoing Sinusoscopy
Chronic Rhinosinusitis, Intraoperative Bleeding
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Blood Loss, Surgical, run by HemoSonics LLC at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparison of Quantra Clot Time results to TEG R results (time frame: Baseline, after induction of anesthesia, before surgical incision). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2021; AzTrials last refreshed its copy on 26 Oct 2026.